两部门聚焦创新药：增设商保创新药目录，构建多元支付体系

Core Viewpoint - The introduction of the "Several Measures to Support the High-Quality Development of Innovative Drugs" by the National Healthcare Security Administration and the National Health Commission aims to address key issues in the innovative drug sector in China, providing comprehensive support across the entire chain from research and development to payment systems [1][5]. Summary by Relevant Sections Support for Innovative Drug Development - The measures include 16 specific actions to enhance the research and development of innovative drugs, improve access to insurance, and promote clinical application [1][2]. - The number of original innovative drug pipelines in China has increased significantly, from 124 in 2015 to 704 by 2024, making China the global leader in this area [3]. - The measures emphasize the importance of data sharing, particularly using healthcare insurance data to guide innovative drug development, thereby improving efficiency [4]. Commercial Health Insurance and Payment Systems - The establishment of a commercial health insurance innovative drug directory is a key highlight, allowing for better integration of commercial insurance with innovative drug access [2][5]. - The measures encourage collaboration between healthcare insurance and commercial health insurance to alleviate the financial burden on basic insurance funds, especially given the high costs associated with innovative drugs [9]. - The new policies aim to create a multi-tiered payment system that supports innovative drug development and encourages the exploration of international markets [9][10]. Clinical Application and Training - The measures promote the training of medical institutions and industry associations to enhance the clinical use of innovative drugs, ensuring that healthcare providers are well-equipped to utilize these new treatments [2][3]. - The focus on real-world research and the integration of clinical experience into the approval and reimbursement processes is expected to improve the overall effectiveness of innovative drugs in clinical settings [2][4]. Regulatory and Policy Framework - The measures propose optimizing the interaction between innovative drug companies and healthcare insurance departments, facilitating smoother communication and policy guidance [5][6]. - The commercial health insurance directory will allow for a more flexible approach to pricing and reimbursement, potentially leading to better access for patients [6][7]. Future Outlook - The implementation of these measures is anticipated to accelerate the development of innovative drugs in China, enhancing the overall healthcare landscape and improving patient access to advanced treatments [10].